Company Overview
Kewaunee Scientific Corporation is a specialized manufacturer dedicated to the design, fabrication, and installation of laboratory, healthcare, and technical furniture alongside essential infrastructure products. The enterprise operates within the Consumer Cyclical sector, specifically targeting the Furnishings, Fixtures & Appliances industry, which implies its performance is closely tied to discretionary spending and capital investment cycles in scientific and medical facilities. This business entity employs a workforce of 1,239 individuals and maintains a total market capitalization of $98.37M with an annualized revenue run rate of $287.75M. These valuation and revenue figures indicate that the company operates as a mid-cap player with a significant operational footprint, generating substantial top-line volume while maintaining a relatively modest market valuation relative to its revenue generation capabilities.
Financial Health
The company reported total revenue of $287.75M for the trailing twelve months, resulting in a net income of $11.08M and an EBITDA of $26.02M. The substantial disparity between the $287.75M revenue and the $11.08M net income reveals a cost structure where operating expenses and taxes consume approximately 96% of gross receipts before reaching the bottom line. Free cash flow stands at $15.47M, a figure that demonstrates the company's ability to generate liquidity from operations after capital expenditures, providing financial flexibility for potential debt servicing or operational adjustments without relying on external financing. Profitability is analyzed through three distinct margins: a gross margin of 28.9%, an operating margin of 3.7%, and a profit margin of 3.9%. The gross margin indicates the efficiency of production costs relative to sales, while the narrow operating and profit margins suggest that operating expenses are a significant burden on the bottom line. Regarding leverage, the balance sheet holds $8.15M in cash against $59.34M in total debt, supported by a debt-to-equity ratio of 81.82, which characterizes the balance sheet as highly leveraged rather than conservative. Liquidity is further assessed by a current ratio of 2.12, indicating that current assets are more than double current liabilities and suggesting a strong capacity to meet short-term obligations. Management effectiveness is quantified by a return on equity of 17.4% and a return on assets of 6.8%, metrics that reveal the company generates significant returns for shareholders relative to the equity base, though asset efficiency is moderated by its high debt load.
Valuation Assessment
Valuation multiples for Kewaunee Scientific Corporation include a trailing twelve-month P/E ratio of 9.23 and a forward P/E of 15.89. The difference between these two metrics, where the forward P/E is significantly higher than the trailing P/E, implies that the market expects earnings to decline in the future or that current earnings are being viewed as temporarily elevated. The stock trades at a price-to-book ratio of 1.39, indicating that the market values the company at approximately 39% above its net asset book value, suggesting a slight premium for the firm's intangible assets or brand equity. Alternative valuation metrics include a price-to-sales ratio of 0.34 and an EV/EBITDA of 5.82, which suggest the stock is priced very cheaply relative to both its sales volume and its cash earnings before interest, taxes, depreciation, and amortization. Price volatility is contextualized by a 52-week high of $60.89 and a 52-week low of $30.33, placing the current trading price roughly 54% below the 52-week high and nearly 10% above the 52-week low. The beta value of 0.58 indicates that the stock's price volatility is less than half that of the broader market, suggesting it behaves as a defensive asset during market fluctuations.
Growth & Income
Growth metrics show a revenue growth rate of 3.3% year-over-year contrasted with an earnings growth rate of -48.9% year-over-year. This divergence implies that while top-line sales are expanding slightly, profitability is contracting sharply, suggesting that cost pressures or margin compression are outpacing revenue gains. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all earnings rather than distributing them to shareholders. Instead of paying dividends, the firm reinvests its cash flow back into the business operations, potentially funding expansion or paying down debt, though the high debt levels may limit aggressive reinvestment strategies. The overall profile combines modest revenue expansion with significant earnings contraction and a lack of income distribution, presenting a scenario where capital preservation is prioritized over shareholder returns.